Sitagliptin improves renal function in diabetic nephropathy in male Sprague Dawley rats through upregulating heme oxygenase-1 expression

Endocrine. 2019 Jan;63(1):70-78. doi: 10.1007/s12020-018-1721-2. Epub 2018 Aug 20.

Abstract

Purpose: Oxidative stress is an important mechanism for diabetic nephropathy. Studies showed that hemo oxygenase-1 (HO-1) expression in renal tissue of patients with diabetic nephropathy has upregulated, while the HO-1 can protect the body through anti-oxidative stress. The study aimed to preliminarily explore the molecular mechanism by observing the effect of Sitagliptin on HO-1 expression in renal tissue of rats with diabetic nephropathy.

Methods: The diabetic nephropathy rat model was established by STZ injection followed by intraperitoneal injection of sitagliptin with different concentrations. The mRNA expressions of HO-1 were detected by real-time PCR and Western blot and HO-1 enzyme activity change was detected by colorimetry. Human renal mesangial cell (HRMC) were cultured in vitro with high glucose concentration (30 μmol/L), phosphatidylinositol-3-kinase (PI3K) level and nuclear factor erythroid-2-related factor (Nrf2) content in cytoplasm and cell nucleus were observed before and after treatment with sitagliptin, as well as the action of in meditating HO-1 expression.

Results: HO-1 mRNA, protein level, and HO-1 enzyme activity in renal tissue of rats with diabetic nephropathy were significantly increased after treatment with sitagliptin (P < 0.05). As comparison, the 24 h urinary microalbumin, creatinine, and boold urea nitrogen were all decreased after treatment of sitagliptin (P < 0.05). Similar results were observed after CoPP (an agonist of HO-1) treatment (P < 0.05). In contrast, ZnPP, an inhibitor of HO-1, significantly abrogated the inhibitory effect of sitagliptin (P < 0.05). Phosphorylation of PI3K and Nrf2 nuclear translocation under high-glucose concentration condition was induced by sitagliptin in HRMC. HO-1 expression was suppressed by pretreating HRMC with PI3K inhibitor or RNA interference.

Conclusions: Sitagliptin may induce HO-1 expression via activation of PI3K and Nrf2 in rats with diabetic nephropathy; HO-1 can improve the oxidative stress of diabetic nephropathy, eventually protect from diabetic nephropathy.

Keywords: Diabetic nephropathy; Heme oxygenase-1; Nuclear factor erythroid-2 related factor (Nrf2); Phosphatidylinositol-3-kinase (PI3K); Phosphoinositide 3-kinase; Sitagliptin.

MeSH terms

  • Animals
  • Cells, Cultured
  • Diabetes Mellitus, Experimental / complications
  • Diabetes Mellitus, Experimental / drug therapy
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / enzymology*
  • Diabetic Nephropathies / pathology
  • Glomerular Mesangium / cytology
  • Glomerular Mesangium / drug effects
  • Glucose / pharmacology
  • Heme Oxygenase (Decyclizing) / biosynthesis*
  • Heme Oxygenase (Decyclizing) / drug effects
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Kidney / pathology
  • Kidney Function Tests
  • Male
  • NF-E2-Related Factor 2 / metabolism
  • Phosphatidylinositol 3-Kinases / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Sitagliptin Phosphate / therapeutic use*
  • Up-Regulation / drug effects

Substances

  • Hypoglycemic Agents
  • NF-E2-Related Factor 2
  • NFE2L2 protein, human
  • Heme Oxygenase (Decyclizing)
  • Hmox1 protein, rat
  • Phosphatidylinositol 3-Kinases
  • Glucose
  • Sitagliptin Phosphate